Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World April 2009 Derek Lowe	Column: In the pipeline The author considers the problems of addressing drug development out of sequence
Chemistry World May 26, 2011 Rebecca Brodie	Nanospray for nanodrugs Teams from the US and Germany have developed a spray drying technique to fabricate drug formulations smaller than 100nm for pharmaceutical trials, improving the drugs' solubility, or bioavailability.
Chemistry World April 2011	Molecular Obesity is Weighing Down Drug Discovery Medicinal chemistry's quest for potent drug candidates has resulted in molecules that are too large and too lipophilic for their own good.
Chemistry World August 2011	Column: In the pipeline Derek Lowe highlights the less visible pitfalls on the road to a new drug
Chemistry World June 2011	Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most.
Chemistry World June 1, 2012 Derek Lowe	Peace, love and understanding You'd think that the chemists and biologists working in drug discovery would understand each other pretty well by now. You would be wrong about that.
Chemistry World June 2008	Column: In the pipeline The author, a medicinal chemist working on preclinical drug discovery, takes a look at the differences between chemists and biologists working on the same team.
Chemistry World March 23, 2010	Comment: Can we halt the flow of new designer drugs? Could the dangers of 'legal high' mephedrone have been predicted? Of course they could, says John Mann
Chemistry World June 2008 Sarah Houlton	Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success
Chemistry World October 2008 Derek Lowe	Column: In the pipeline The author seeks a cure for 'compound bloat'
Chemistry World July 2010	Column: In the pipeline Derek Lowe ponders the possibility of phosphatase inhibitors
Chemistry World September 25, 2015 Derek Lowe	Spice up your compounds You and your team are optimizing a lead compound, as medicinal chemists are wont to do -- varying its structure to improve its potency, selectivity and other properties.
Chemistry World January 2011	Column: In the pipeline Some medicinal chemists can't get enough fluorines in their molecules. The love-hate relationship is explained.
The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.
Chemistry World July 26, 2012 Derek Lowe	Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time.
Chemistry World January 2009 Derek Lowe	Column: In the pipeline The author discusses the age-old tradition of passing the buck in drug development.
Chemistry World February 3, 2011 Ben Merison	The mystery of the disappearing crystals UK chemists have analysed a fifty year old sample to find out why and say that it's down to impurities. This takes researchers a step closer to understanding why certain pharmaceutical drugs lose their therapeutic effect.
The Motley Fool June 3, 2011 Frank Vinluan	GSK Sees Positive Results on Asthma, COPD Drug Expected to Succeed Advair GSK gets good news.
Chemistry World March 2011	Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
Chemistry World November 2008 Derek Lowe	Column: In the pipeline Drug discovery chemists live by assay data; we depend on these numbers to tell us if we're heading in the right direction with our molecules.
Chemistry World August 2007 Derek Lowe	Opinion: In the Pipeline Process chemists just don't get the credit they deserve.
The Motley Fool July 12, 2010 Ryan McBride	Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009.
Chemistry World October 2010	Column: In the pipeline Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery
Chemistry World September 2008 Derek Lowe	Column: In the pipeline The author remembers leaving the ivory towers of academe to trade 'unusual and beautiful' for 'useful'
The Motley Fool April 26, 2011 Brian Orelli	We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants.
Chemistry World December 2009	Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
American Journal of Nursing October 2009	Drug Administration Through an Enteral Feeding Tube Guidelines for the safe administration of drugs through an enteral feeding tube are available, but research shows that often nurses don't adhere to them.
The Motley Fool March 4, 2010 Brian Orelli	A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
Chemistry World June 17, 2015 James Urquhart	Promising compound offers single dose knock-out for malaria Ian Gilbert and colleagues, working with the Medicines for Malaria Venture, have found a compound dubbed DDD107498 which kills Plasmodium falciparum -- the species responsible for most dangerous form of malaria.
Chemistry World August 2009 Derek Lowe	Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder
Chemistry World June 2010	Column: In the pipeline Derek Lowe looks into his crystal ball to see what the future of medicinal chemistry might be
Chemistry World July 30, 2015 Derek Lowe	A precision instrument? How much do medicinal chemists and their biology colleagues really trust each other's data? In the end, they have to, because drug discovery is a team sport.
Chemistry World June 18, 2015 Emma Stoye	Crowdsourcing compounds to tackle antibiotic resistance Chemists around the world are being called on to donate samples of novel compounds they have synthesized to a crowdsourcing project that aims to find new antibiotics.
Reactive Reports Issue 56 Jeffrey Krise	A Basic Approach to Chemotherapy Chemists have found a way to attack malignant cells with an anticancer drug, while sparing healthy cells.
Chemistry World April 2011	Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
Chemistry World July 2008 Kevin Rogers	What future for small molecule therapy? Pharmaceutical companies overlook bench chemists at their peril
Chemistry World June 2007 Derek Lowe	Opinion: In the Pipeline A medicinal chemist experienced in pre-clinical drug discovery sets the record straight about pharmaceutical patents on traditional medicines.
The Motley Fool January 25, 2010 Brian Orelli	No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday.
The Motley Fool April 29, 2011 Brian Orelli	Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya.
Chemistry World April 8, 2013 Sarah Houlton	India rejects Novartis patent appeal India's Supreme Court has denied Novartis' appeal against the decision to refuse patent protection for its anticancer drug Glivec (imatinib mesylate).
Chemistry World August 2008	Column: In the pipeline Problems develop when there are too few workhorse reactions, which may well generate compounds that are too similar to each other. Are we at that stage now?
Chemistry World December 2008	Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
Chemistry World January 2, 2013 Derek Lowe	Fear of the unknown My mental file drawer labelled 'Terrible Reagents I Have Known' is even larger than the one called 'Lunatics I Have Worked With and their Life-Threatening Ideas'. We organic chemists really do work with some terrible chemicals, and it's up to us to keep them from causing havoc.
The Motley Fool September 28, 2010 Brian Orelli	Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs.
Chemistry World November 27, 2013 Derek Lowe	Rolling boulders uphill A lot of preclinical projects don't even get off the ground, and many that do still never deliver anything to the development groups.